Investor's Business Daily on MSN15m
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback